Darapladib for preventing ischemic events in stable coronary heart disease

• Main Authors: Harvey D. White, Claes Held, Ralph Stewart, Elizabeth Tarka, Rebekkah Brown, Richard Y. Davies, Andrzej Budaj, Robert A. Harrington, P. Gabriel Steg, Diego Ardissino, Paul W. Armstrong, Alvaro Avezum, Philip E. Aylward, Alfonso Bryce, Hong Chen, Ming Fong Chen, Ramon Corbalan, Anthony J. Dalby, Nicolas Danchin, Robbert J. De Winter, Stefan Denchev, Rafael Diaz, Moses Elisaf, Marcus D. Flather, Assen R. Goudev, Christopher B. Granger, Liliana Grinfeld, Judith S. Hochman, Steen Husted, Hyo Soo Kim, Wolfgang Koenig, Ales Linhart, Eva Lonn, José López-Sendón, Athanasios J. Manolis, Emile R. Mohler, José C. Nicolau, Prem Pais, Alexander Parkhomenko, Terje R. Pedersen, Daniel Pella, Marco A. Ramos-Corrales, Mikhail Ruda, Mátyás Sereg, Saulat Siddique, Peter Sinnaeve, Peter Smith, Piyamitr Sritara, Henk P. Swart, Rody G. Sy, Tamio Teramoto, Hung Fat Tse, David Watson, W. Douglas Weaver, Robert Weiss, Margus Viigimaa, Dragos Vinereanu, Junren Zhu, Christopher P. Cannon, Lars Wallentin
• Other Authors: University of Auckland
• Format: Article
• Published: 2018
• Subjects: Medicine
• Online Access: https://repository.li.mahidol.ac.th/handle/123456789/34884

BACKGROUND: Elevated lipoprotein-associated phospholipase A2 activity promotes the development of vulnerable atherosclerotic plaques, and elevated plasma levels of this enzyme are associated with an increased risk of coronary events. Darapladib is a selective oral inhibitor of lipoprotein-associated...